Pharmaceuticals

Anti-HER2 Bispecific ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for the Treatment of HER2-positive Breast Cancer

SUZHOU, China, Feb. 6, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (...

2025-02-06 14:05 4258

Argent BioPharma: A Hidden Gem traded Under $12M--Edison Group Report Assigned a $327M Valuation to Its Breakthrough Epilepsy Treatment

PERTH, Australia, Feb. 6, 2025 /PRNewswire/ -- Argent BioPharma (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company brings hope to epilepsy patients. For thousands of patients with refractory epilepsy—commonly referred to as drug-resistant epilepsy—the search for effective trea...

2025-02-06 05:00 3000

Actinogen announces new and unique nonproprietary name of 'emestedastat' for Xanamem

Late-stage Alzheimer's trial opens 10 new sites in USA, with results due in 2025 and 2026 SYDNEY, Feb. 5, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that the World Health Organization (WHO) has granted the nonproprietary name of 'emestedastat' to Actinogen for its Xaname...

2025-02-05 22:18 3675

Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

* Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC * Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) for the treatment of ES-SCLC * Serplulimab has now been approved in China, Europe, and sev...

2025-02-05 22:05 4712

I Peace establishes and offers low immunoreaction risk GMP iPS Cells

Three lines of GMP iPS Cells derived from type O female blood are now offered  as off-the-shelf product PALO ALTO, Calif., Feb. 5, 2025 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (https://ipeace.com/en/ ), specializing in induced pluripotent stem cells (iPSCs) and...

2025-02-05 22:00 2893

From 0 to 100 Trillion: The Rise of Sanyou Bio's Intelligent Molecule Library

SHANGHAI, Feb. 5, 2025 /PRNewswire/ -- In the field of biopharmaceuticals, every technological innovation has the potential to revolutionize treatment strategies. Sanyou Bio's Intelligent Hundred-Trillion Molecule Library (AI-STAL) has emerged from scratch as a shining star, forged through a deca...

2025-02-05 18:00 2587

China Medical University and Healthcare System Pioneers AI-Driven Drug Discovery and Allogeneic CAR-T Therapy: A Groundbreaking Leap in Cancer Treatment

TAICHUNG, Feb. 5, 2025 /PRNewswire/ -- Healthcare Expo Taiwan is a professional-oriented exposition involving healthcare, information/communication, technology, biopharmaceutical and medical device industries. Attended by healthcare professionals from all over the world, the Expo showcases the l...

2025-02-05 13:00 3769

Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 4, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunol...

2025-02-05 12:28 3085

Sequins™ Announces Availability of First Products - Bolsters Team for Commercialization

SAN FRANCISCO, Feb. 4, 2025 /PRNewswire/ -- Sequins, a newly-funded start-up in the next generation sequencing (NGS) ecosystem, announced today the availability of their first commercial products – the Sequins Metagenomics Core Control and Whole Genome Sequencing Core Control Sets, along with an ...

2025-02-05 00:00 2526

GC Labs strengthens global ties and explores new opportunities at Medlab Middle East 2025

YONGIN, South Korea, Feb. 4, 2025 /PRNewswire/ -- GC Labs, a leading clinical laboratory inSouth Korea, announced the successful completion of the second day of the Medlab Middle East 2025, which is being held at theDubai World Trade Centre (DWTC), UAE betweenFebruary 3-6.

2025-02-04 14:56 3163

LabConnect Announces Formation of Strategic Advisory Board and Appointment of Inaugural Members

JOHNSON CITY, Tenn., Feb. 4, 2025 /PRNewswire/ -- LabConnect, a leading provider of central lab services and functional service provider solutions, is proud to announce the formation of its Strategic Advisory Board and the appointment of its inaugural members. This board will further cement LabC...

2025-02-04 02:02 3464

China Jo-Jo Drugstores Announces Strategic Business Restructuring to Strengthen Wholesale Business for Greater Profitability and Growth

HANGZHOU, China, Feb. 3, 2025 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced it has...

2025-02-03 21:00 5702

Nona Biosciences Announces Strategic Collaboration with Invetx for Next-Generation Animal Health Biotherapeutics Discovery

CAMBRIDGE, Mass., Feb. 3, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I TM), announced today that it has entered into a strategic collaboration with Invetx, Inc. ("Invetx"), aBoston-based animal biotechnology company...

2025-02-03 20:00 2804

Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

MELBOURNE, Australia and INDIANAPOLIS, Jan. 31, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition from antibody engineering company ImaginAb, Inc. (ImaginAb). The acquisition includes a pipeline of next...

2025-01-31 06:01 5229

A Total of USD 12.7 Million Investment in New Diagnostics and Drug Development for NTDs and Malaria to Partners Including the Ohio State University, PATH, GSK and Others

TOKYO, Jan. 30, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximatelyJPY 2 billion ( USD 12.7 million1) in eight projects for the development of new diagnostics and drugs for neglected tropical diseases (NTDs) and malaria.2  J...

2025-01-30 10:00 4341

Asia Book of Records Honors Cipla (Emerging Markets & Europe business unit) for Record-Breaking Doctor engagement on COPD Awareness Initiative

Cipla's (EMEU BU) 'Take Charge – I Pledge' campaign engaged 4,350 doctors across six countries, setting a new benchmark in raising COPD awareness. MUMBAI, India, Jan. 29, 2025 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as "Cipla" today announced that itsEmerging Marke...

2025-01-29 20:09 7116

Telix Completes Acquisition of RLS (USA) Inc.

MELBOURNE, Australia and INDIANAPOLIS, Jan. 28, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition of RLS (USA) Inc. (RLS; RLS Radiopharmacies), America's only Joint Commission-accredited radiopharmacy n...

2025-01-28 05:40 8397

CStone Partners with SteinCares to Market Sugemalimab in Latin America

* CStone will receive upfront, regulatory and commercial milestone payments, and book revenue from SteinCares through the supply of sugemalimab in 10 Latin American (LATAM) countries. * This marks CStone's third major global commercialization partnership for sugemalimab, with additional deals...

2025-01-27 12:30 3758

Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA

HONG KONG, Jan. 26, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted by the Center for Drug Evaluation (CDE) of the N...

2025-01-27 09:53 3385

CARiNG Pharmacy Celebrates Consecutive Gold Triumph at the 2024 Putra Aria Brand Awards

KUALA LUMPUR, Malaysia, Jan. 27, 2025 /PRNewswire/ -- CARiNG Pharmacy is thrilled to announce its back-to-back victory in securing the Gold award in the retail category at the 2024 Putra Aria Brand Awards. This recognition highlights the brand's unwavering commitment to excellence in the retail ...

2025-01-27 08:33 4387
1 ... 100101102103104105106 ... 345

Week's Top Stories